Adherence, MedicationPDTNCCPNCT07864532
Prevalence and Determinants of Therapeutic Non-Compliance in Patients With Chronic Pathologies ( PDTNCCP)
An observational study of Adherence, Medication, run by University of Monastir at 1 site in Tunisia.
Trial summary
Identify the prevalence and determinants related to therapeutic non adherence among patients with chronic pathologies and to design effective interventions optimizing treatment compliance. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Adherence, Medication
- How many people
- 3,000 participants
- Where
- 1 siteTunisia
- Study dates
- 1 Mar 2024to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with a prescription for a chronic disease and who accept to enroll in this study.
Who may be able to join
- Patients with a history of arterial hypertension (HTA), diabetes, obstructive pulmonary disease (COPD), and heart failure (HF), isolated or combined.
- Patients who have been under treatment for more than 6 months.
Who cannot join
- Non-cooperative or non-consenting patients.
- Patients unable to understand spoken words, such as those with visual or hearing impairment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prevalence and Determinants of Therapeutic Non-compliance in Patients With Chronic Pathologies
Identify the prevalence and determinants related to therapeutic non adherence among patients with chronic pathologies and to design effective interventions optimizing treatment compliance.
Read the detailed description
Medication non-adherence is a major problem leading to accelerated disease progression, increased morbidity and mortality, and additional costs to health systems.This is why the main objectif of this study is to identify factors that influence therapeutic adherence and to design effective interventions optimizing treatment compliance.
This study is a cross-sectional descriptive survey taking place at the emergency department of the Fattouma Bourguiba hospital in Monastir and at regional hospitals of the city of Monastir.
- Conditions
- Adherence, Medication
- Keywords
- Therapeutic non-compliance, Prevalence, Chronic Pathologies, Diabetes, Chronic Heart Failure, Obstructive Pulmonary Disease, Arterial Hypertension
- Medical subject headings
- Medication Adherence, Diabetes Mellitus, Lung Diseases, Obstructive, Hypertension
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence measured using the 8-item Morisky Medication Adherence Scale (MMAS-8)
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). The scale assesses patients' medication-taking behavior, including forgetting doses, discontinuing treatment, difficulties with daily medication use, and other behaviors related to medication adherence. The MMAS-8 score ranges from 0 to 8, with higher scores indicating higher medication adherence.
Measured: Baseline
Secondary outcomes (1)
Factors associated with medication adherence
Demographic, clinical, and treatment-related characteristics will be collected and analyzed to identify factors associated with medication adherence as measured by the MMAS-8 score.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start1 Mar 2024
- Primary completion31 May 2024
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adherence, MedicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Monastir
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pr. Semir Nouira, University of Monastir
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864532
- Sponsor's protocol ID
- Therapeutic Non Compliance
- Acronym
- PDTNCCP
- Status last verified
- Oct 2026
- First submitted
- 5 Apr 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence and Determinants of Therapeutic Non-compliance in Patients With Chronic Pathologies
- ClinicalTrials.gov ID
- NCT07864532
- Acronym / sponsor ID
- PDTNCCP / Therapeutic Non Compliance
- Conditions
- Adherence, Medication
- Keywords
- Therapeutic non-compliance, Prevalence, Chronic Pathologies, Diabetes, Chronic Heart Failure, Obstructive Pulmonary Disease, Arterial Hypertension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,000 participants (actual)
- Lead sponsor
- University of MonastirUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 31 May 2024 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Identify the prevalence and determinants related to therapeutic non adherence among patients with chronic pathologies and to design effective interventions optimizing treatment compliance.
Detailed description
Medication non-adherence is a major problem leading to accelerated disease progression, increased morbidity and mortality, and additional costs to health systems.This is why the main objectif of this study is to identify factors that influence therapeutic adherence and to design effective interventions optimizing treatment compliance.
This study is a cross-sectional descriptive survey taking place at the emergency department of the Fattouma Bourguiba hospital in Monastir and at regional hospitals of the city of Monastir.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with a prescription for a chronic disease and who accept to enroll in this study.
Key inclusion criteria (2 listed)
- Patients with a history of arterial hypertension (HTA), diabetes, obstructive pulmonary disease (COPD), and heart failure (HF), isolated or combined.
- Patients who have been under treatment for more than 6 months.
Key exclusion criteria (2 listed)
- Non-cooperative or non-consenting patients.
- Patients unable to understand spoken words, such as those with visual or hearing impairment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Adherence measured using the 8-item Morisky Medication Adherence Scale (MMAS-8)
Time frame: Baseline
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). The scale assesses patients' medication-taking behavior, including forgetting doses, discontinuing treatment, difficulties with daily medication use, and other behaviors related to medication adherence. The MMAS-8 score ranges from 0 to 8, with higher scores indicating higher medication adherence.
1 secondary outcome
Factors associated with medication adherence
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Adherence, Medication
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Not yet recruiting
A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes: A Randomized Controlled Trial
Medication Adherence, Glycemic Control for Diabetes Mellitus
Not yet recruiting
Assessing Psoriasis Treatment Outcomes
Psoriasis
Active, not recruiting
HERDA: Pharmacist-Led Culturally Adapted Intervention for Depression Medication Adherence
Depression
Not yet recruiting
Asthma Ctrl SMART Trial
Asthma in Children, Asthma Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adherence, Medication, run by University of Monastir at 1 site in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adherence measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.